Literature DB >> 2160537

Oligosaccharide mapping of low molecular weight heparins: structure and activity differences.

R J Linhardt1, D Loganathan, A al-Hakim, H M Wang, J M Walenga, D Hoppensteadt, J Fareed.   

Abstract

Low molecular weight heparins from a variety of commercial sources were examined. These had been prepared by several methods including peroxidative cleavage, nitrous acid cleavage, chemical beta-elimination, enzymatic beta-elimination, and chromatographic fractionation. The molecular weight and polydispersity of these low molecular weight heparins showed greater differences than were observed for typical commercial heparin preparations. Considerable differences were also observed in the antithrombin III mediated anti factor Xa activity, the heparin cofactor II mediated antifactor IIa activity, and the USP activity of these low molecular weight heparins. An oligosaccharide-mapping technique (comparable to the peptide mapping of proteins) was applied to these low molecular weight heparins in an effort to understand the structural features responsible for their activity differences. Heparin lyase from Flavobacterium heparinum was first used to depolymerize the low molecular weight heparin into its constituent oligosaccharides. The oligosaccharides present in the resultant mixture were identified and quantitated by using standard oligosaccharides of defined structure on gradient polyacrylamide gel electrophoresis and strong anion exchange high pressure liquid chromatography. Six of the oligosaccharide products have been identified and represent nearly 90 wt % of heparin's mass. Even though all the low molecular weight heparins showed these six oligosaccharide components, their content in each varied greatly, accounting for 20 to over 90% of their mass. The antithrombin III mediated anti factor Xa activities of the low molecular weight heparins correlated only poorly to the concentration of a hexasaccharide containing a portion of heparin's antithrombin III binding site. The heparin cofactor II mediated antifactor IIa activity, however, could not be correlated to these six oligosaccharides of known structure nor to the molecular weight or charge density of these low molecular weight heparins. The low molecular weight heparins prepared by different methods each showed a new distinctive oligosaccharide in their maps. Their isolation and structural characterization, which included two-dimensional NMR and fast atom bombardment mass spectrometry, indicated that these unusual oligosaccharides result from end-sugar modification during chemical depolymerization. Both gel electrophoresis and high-pressure liquid chromatography mapping techniques showed a greater structural diversity between low molecular weight heparins than had previously been observed between similarly analyzed commercial heparins.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2160537     DOI: 10.1021/jm00168a017

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

1.  Structural characterization of heparins from different commercial sources.

Authors:  Fuming Zhang; Bo Yang; Mellisa Ly; Kemal Solakyildirim; Zhongping Xiao; Zhenyu Wang; Julie M Beaudet; Amanda Y Torelli; Jonathan S Dordick; Robert J Linhardt
Journal:  Anal Bioanal Chem       Date:  2011-09-20       Impact factor: 4.142

2.  Structural features of glycol-split low-molecular-weight heparins and their heparin lyase generated fragments.

Authors:  Anna Alekseeva; Benito Casu; Giuseppe Cassinelli; Marco Guerrini; Giangiacomo Torri; Annamaria Naggi
Journal:  Anal Bioanal Chem       Date:  2013-11-20       Impact factor: 4.142

3.  Molecular weight and concentration of heparin in hyaluronic acid-based matrices modulates growth factor retention kinetics and stem cell fate.

Authors:  Amit K Jha; Anurag Mathur; Felicia L Svedlund; Jianqin Ye; Yerem Yeghiazarians; Kevin E Healy
Journal:  J Control Release       Date:  2015-04-27       Impact factor: 9.776

Review 4.  New data on the pharmacology of heparin and low molecular weight heparins.

Authors:  M M Samama; L Bara; I Gouin-Thibault
Journal:  Drugs       Date:  1996       Impact factor: 9.546

5.  Photochemical Preparation of a Novel Low Molecular Weight Heparin.

Authors:  Kyohei Higashi; Saori Hosoyama; Asami Ohno; Sayaka Masuko; Bo Yang; Eric Sterner; Zhenyu Wang; Robert J Linhardt; Toshihiko Toida
Journal:  Carbohydr Polym       Date:  2012-02-01       Impact factor: 9.381

6.  Design of hydrogels to stabilize and enhance bone morphogenetic protein activity by heparin mimetics.

Authors:  Soyon Kim; Zhong-Kai Cui; Paul Jay Kim; Lawrence Young Jung; Min Lee
Journal:  Acta Biomater       Date:  2018-03-26       Impact factor: 8.947

7.  Competitive inhibition of heparinase by persulfonated glycosaminoglycans: a tool to detect heparin contamination.

Authors:  Udayanath Aich; Zachary Shriver; Kannan Tharakaraman; Rahul Raman; Ram Sasisekharan
Journal:  Anal Chem       Date:  2011-09-19       Impact factor: 6.986

8.  Ozonolysis of the double bond of the unsaturated uronate residue in low-molecular-weight heparin and K5 heparosan.

Authors:  Sayaka Masuko; Kyohei Higashi; Zhenyu Wang; Ujjwal Bhaskar; Anne Marie Hickey; Fuming Zhang; Toshihiko Toida; Jonathan S Dordick; Robert J Linhardt
Journal:  Carbohydr Res       Date:  2011-06-22       Impact factor: 2.104

9.  Characterizing the microstructure of heparin and heparan sulfate using N-sulfoglucosamine 1H and 15N NMR chemical shift analysis.

Authors:  Derek J Langeslay; Consuelo N Beecher; Annamaria Naggi; Marco Guerrini; Giangiacomo Torri; Cynthia K Larive
Journal:  Anal Chem       Date:  2012-12-31       Impact factor: 6.986

10.  A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids.

Authors:  Brian L Henry; Bernhard H Monien; Paul E Bock; Umesh R Desai
Journal:  J Biol Chem       Date:  2007-09-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.